Gilead Sciences, Inc.
Gilead Sciences, Inc. reported 5 US-listed holdings worth $1.65 billion in its 13F for the quarter ended 30 June 2026, filed 3 August 2026. Its largest: Arcus Biosciences, Inc. (58.8%), Galapagos NV (30.3%) and Assembly Biosciences Inc. (8.3%). Against the quarter before, it opened 0 positions, added to 1, trimmed 0 and sold out of 1.
Reported holdings$1.65B-22.1% on Q1 2026
Positions5-1 on Q1 2026
The largest ten100.0%of its reported holdings
Latest 13FQ2 2026filed 3 August 2026
Added toHeld
The 5 largest of its 5 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Added 1Held 4Sold out 1
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Added to 1
- Assembly Biosciences Inc. ASMB+471,698 shares · +10%
Sold out of 1
- Arcellx Inc. ACLX$771.7 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Arcus Biosciences, Inc. RCUS | 31,424,760 | $968.8 million | 58.76% | no change |
| Galapagos NV LKFT | 16,707,477 | $500.2 million | 30.34% | no change |
| Assembly Biosciences Inc. ASMB | 4,977,089 | $136.8 million | 8.30% | +471,698 |
| Kyverna Therapeutics Inc. KYTX | 4,126,119 | $36.8 million | 2.23% | no change |
| Xilio Therapeutics Inc. XLO | 650,389 | $6.2 million | 0.38% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.